Labiana to join IBEX Growth Market 15 after trading value surges

Labiana will enter the IBEX Growth Market 15 on 21 September after its traded value climbed to €9.35 million by 16 September, nearly triple its full-year 2025 total. The move boosts healthcare representation in the index and gives the Spanish pharmaceutical group a bigger profile in the market.

Why it matters: - Labiana’s move into the IBEX Growth Market 15 can increase the company’s visibility with investors and broaden its shareholder base. - The addition also strengthens healthcare and life sciences representation in the index. - Retail participation is already high in the Healthcare sector of the IBEX Growth Market 15, which can support trading interest.

What happened: - Labiana will join the IBEX Growth Market 15 on 21 September 2026. - The index adjustment will take place after the close of trading on Friday, 18 September, following an ordinary review by the Technical Advisory Committee. - Alquiber, Biotechnology Assets, Catenon and Indexa Capital will join the index alongside Labiana. - Labiana is a Spanish pharmaceutical group focused on animal and human health medicines.

The details: - The IBEX Growth Market 15 includes the 15 BME Growth securities with the highest free-float-adjusted market capitalisation among those meeting BME liquidity requirements. - Labiana’s inclusion reflects gains in free-float-adjusted market capitalisation, trading activity and liquidity compliance. - The company’s shares traded value reached €9.35 million as of 16 September 2026. - That figure was nearly three times Labiana’s full-year 2025 traded value of €3.30 million. - Labiana’s traded value in 2024 was €2.75 million. - Labiana’s market capitalisation exceeded €52 million on 16 September 2026. - Labiana’s market capitalisation was €34.95 million at the end of 2025. - The Healthcare-sector securities in the index drew retail investors for 83.88% of purchase transaction volume and 75.26% of sale transaction volume in 2025, according to CNMV data. - Labiana will join Biotechnology Assets in the index, while Vytrus Biotech is already a constituent. - Labiana’s inclusion comes after stronger trading activity in 2026.

Between the lines: - The index addition suggests Labiana has crossed a market-maturity threshold, not just an operational one. - Higher traded value and market capitalisation can improve liquidity and make the stock more accessible to a wider investor base. - The healthcare cluster in the index may continue to attract retail interest if sector trading remains active.

What’s next: - Labiana’s new index membership will begin after the 18 September close and take effect on 21 September. - The company will look to use the index inclusion to expand market awareness and shareholder participation. - Continued trading activity will likely help determine whether Labiana holds its stronger position in future reviews.

The bottom line: - Labiana’s jump into the IBEX Growth Market 15 caps a sharp rise in trading and market value, giving the Spanish pharma group a more prominent place in Spain’s growth-market lineup.